Pharmaceutical Technology\'s In the Lab eNewsletter-01-09-2019

Unprocessed bulk material harvested directly from the bioreactor should be tested for contamination prior to downstream processing.

Fluorescence has long been used to detect biological targets. As these measurements are becoming more and more quantitative, standards are needed to ensure accuracy and reproducibility.

The companies entered a license agreement for the Trianni Mouse, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies (mAbs), to support MacroGenics’ discovery programs for mAb-based therapeutics.

A new plasma B cell antibody discovery workflow launched by Berkeley Lights enables the shortening of antibody drug discovery from month to a day.

The new reagents are designed to support clinical-phase and commercialization stages of cell and gene therapy production and to enhance DNA transfection.

The Steritest NEO device from MilliporeSigma provides safer pharmaceutical product testing through additional features.

Eli Lilly and AC Immune have signed a license and collaboration agreement focussing on the R&D of tau aggregation inhibitor small molecules for the potential treatment of neurodegenerative diseases.

The merged companies will provide histopathology services in the research and pre-clinical therapeutics markets.

New FDA guidance developed to identify lapses in data integrity and promote best practices.

TrendMiner 2018.R2 software for analysis of time-series data includes the ContextHub platform for expanded, self-service analytics capabilities.